Home/Pipeline/B7-H3 Targeted Antibody

B7-H3 Targeted Antibody

Solid Tumors

PreclinicalActive

Key Facts

Indication

Solid Tumors

Phase

Preclinical

Status

Active

Company

Ocean Biomedical

About Ocean Biomedical

Ocean Biomedical is a biopharmaceutical company focused on translating groundbreaking academic research into novel therapeutics. Its strategy involves in-licensing and developing a diversified pipeline of drug candidates targeting oncology, fibrosis, and infectious diseases. The company went public via a SPAC merger in 2023, providing capital to advance its lead programs into clinical development. Its approach centers on identifying and validating new biological pathways to create first-in-class or best-in-class treatments.

View full company profile

Therapeutic Areas

Oncology Fibrotic Diseases Infectious Diseases

Other Solid Tumors Drugs

Drug	Company	Phase	Status
GSK4362676	GSK plc	Phase 1	Active
ABBV-154	AbbVie	Phase 1	Active
TAK-981	Takeda Pharmaceutical	Phase 1/2	Active
TAK-676	Takeda Pharmaceutical	Phase 1	Active
TAK-573	Takeda Pharmaceutical	Phase 1	Active
TAK-164	Takeda Pharmaceutical	Phase 1	Active
SHR-1316	Jiangsu Hengrui Medicine	Phase 1/2	Active
BAY 2927088	Bayer	Phase 1	Active
ASP1929	Astellas Pharma	Phase 2	Active
IBI188	Innovent Biologics	Phase 1	Active
Bispecific Antibody	Akeso	Phase 1/2	Active
CSPC-DM02	CSPC Pharmaceutical Group Limited	Phase 2	Active